COVID-19 and endocrine and metabolic disorders: critical points and suggestions for a correct therapeutic management from a tertiary endocrine center in Italy

Minerva Endocrinol (Torino). 2022 Mar;47(1):117-126. doi: 10.23736/S2724-6507.21.03523-5. Epub 2021 Jul 26.

Abstract

The Coronavirus-19 (COVID-19) pandemic, which began in December 2019 in Wuhan, China, has spread rapidly worldwide, affecting mostly frail individuals and resulting in high lethality among people with chronic conditions. The management of chronic endocrine disorders during the pandemic period proved particularly challenging, as they require close physician-patient contact for proper long-term management. In addition, acute endocrinologic conditions that presented during the COVID-19 period required timely management in an unusual clinical setting, providing an ongoing challenge for clinicians. This article summarizes the most recent guidance on the management and therapy of frequent conditions such as diabetes and osteoporosis and less common endocrine disorders (e.g., adrenal insufficiency) in this setting.

MeSH terms

  • Adrenal Insufficiency*
  • COVID-19*
  • Diabetes Mellitus* / epidemiology
  • Humans
  • Pandemics
  • SARS-CoV-2